Home 2019-08-30T20:34:50+00:00

Klox Technologies

Klox is a private biomedical technology innovator that targets specific skin and soft tissue conditions by controlling the benefits of fluorescence generated energy to penetrate and manage the skin from within. The unique products we bring to the market stimulate the skin’s own biological processes and repair mechanisms, which demonstrate high safety and efficacy, helping clinicians improve patient outcomes without compromise.

Our technology induces Fluorescence Biomodulation (FB), which has shown to impact cellular signaling pathways in the skin. We research, develop, and commercialize solutions based on our fluorescence-generating technology for a growing and aging population that is seeking more effective and less invasive options to improve their health.

Clinical Solutions

Explore our Portfolio

Explore our Technology

Klox products are applied to the skin and activated by LED light for a short exposure period lasting under ten minutes.

Light interacts with light absorbing molecules (LAM) embedded within the Klox gel to generate fluorescent energy.

Klox is a medical device company that transforms lives through its innovative Fluorescence Biomodulation technology.  Read more.

Wound Care

Wound care specialists and patients require innovation that can predictably heal chronic wounds. Advanced wound care generates more than $9 billion in costs, driven by difficulties in hard to heal wounds, an aging population and an increasing demand for homecare treatments.

LumiHeal™ is a globally patented wound care solution, supported by scientific evidence (five clinical studies) and a CE mark in Europe.

Partnering

Klox invests in the development, innovation and delivery of launch-ready technology and products. To commercialize our Fluorescence Biomodulation technology, we rely on investment capital and long-term business partners with expertise in our therapeutic categories.

We are offering our high growth LumiHeal™ wound care system and our late-stage Phovia™ veterinary system for strategic partnerships.

Trusted Collaborators

At Klox, we always strive to build and invest in our science, technology, and engineering expertise. To challenge the conventions of the industry, we extend our capabilities by collaborating with leading professionals and cutting-edge scientific facilities, wherever they may be. Our extended network is critical for maintaining vitality and scientific rigor in our mission to bring Fluorescence Biomodulation to patients in need.

News & Events

August 30, 2019

August 19-22, 2019

Military Health System Research Symposium – Florida, United States

June 10-15, 2019

June 5-7, 2019

May 16-17, 2019

VetCon – Cork, Ireland

May 3-4, 2019

March 20-21, 2019

March 15-17, 2019

La Chirurgia Estetica– Florence, Italy

March 8, 2019

March 7, 2019

LumiHeal was granted the Canadian Medical Device License (MDL) for “the management of post-surgical closed wounds and to help in the prevention of hypertrophic scars and post-surgical wound complications in patients 18 years and older”

March 1, 2019

Fluorescence Biomodulation has been added to various sections in the Journal of Wound Care’s 2019 peer-reviewed International Consensus Document – Implementing TIMERS: the race against hard-to-heal wounds

February 26-27, 2019

Animal Health Investment Europe – London, England

February 2-7, 2019

SPIE Photonics West – San Francisco, USA

January 30, 2019

LumiHeal Newsletter – Updates On Our Lead Wound Care Product

January 20-22, 2019

Journées Cicatrisations – Paris, France

January 7-10, 2019

J.P. Morgan Healthcare Conference – San Francisco, USA

November 5-7, 2018

Wounds UK – Harrogate, UK

November 4, 2018

September 24-26, 2018

The MedTech Conference – Philadelphia, USA

September 12-14, 2018

July 2, 2018

Klox announces positive top-line results from a pivotal study of Phovia™ for the management of Canine Deep Pyoderma – See Full Press Release

June 13-14, 2018

June 4-7, 2018

May 9-11, 2018

May 2-3, 2018

April 25-29, 2018